Vascular endothelial growth factor blockade elicits a stable metabolic shift in tumor cells: therapeutic implications.
The metabolism of tumors differs remarkably from that of normal tissues, but whether this is a stable feature of tumor cells is largely unknown. Recent findings by independent teams indicate that antiangiogenic drugs cause a metabolic shift in tumor cells that is associated with increased malignancy. These results suggest therapy-driven evolutionary dynamics of tumor metabolism that could be therapeutically targeted.
Immunology and Molecular Oncology Unit; Istituto Oncologico Veneto-IRCCS ; Padova, Italy.
Stefano
S
Indraccolo
VEGF; antiangiogenic therapy; cancer; glycolysis; metabolism